Beximco Pharmaceuticals Limited announced the signing of a commercial agreement for distribution of certain products of Mylan in Bangladesh. Under the terms of the agreement, Beximco Pharma will receive the exclusive rights to launch Mylan's portfolio of key monoclonal antibodies to treat different types of cancers, rheumatoid arthritis, Chron's disease, ulcerative colitis and other medical conditions. The first product to be launched, in first quarter 2020, will be Ogivri™, a breast cancer drug which is biosimilar to blockbuster drug Herceptin from Roche with global sales in excess of $7 billion in 2018.

Ogivri is approved the U.S. Food and Drug Administration . and also has received marketing authorisation from the European Medicines Agency. Cancer is now one of the leading causes of death in Bangladesh and currently there are more than 50,000 HER2-positive breast cancer patients in the country.